Cyclacel Announces Completion of Enrollment in Phase 2 Trial of Sapacitabine in Elderly AML

News source: Business Wire Cyclacel Pharmaceuticals, Inc. announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company's oral nucleoside analogue, in elderly patients with acute myeloid leukemia (AML). Interim results from this trial are expected to be available by the end of 2008 and final results during the second half of 2009. "The randomized Phase 2 study of sapacitabine in patients with elderly AML and myelodysplastic syndromes (MDS) achieved its enrollment target of the AML stratum in accordance with the protocol approximately three months ahead of forecast," said Dr. Judy Chiao, M.D., Vice President, Clinical Development and Regulatory Affairs of Cyclacel. "We are grateful for the contributions of our investigators, their colleagues and patients who helped us... [read full story]